Research & Access Updates

— Monday, September 21, 2020

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

SpringWorks Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing life-chan...

Read more

— Thursday, September 17, 2020

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM):

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior e...

Read more

— Wednesday, August 19, 2020

More on ASCO 2020

At the end of May, myeloma researchers would have flocked to Chicago for the 56th Annual Meeting of the A...

Read more

— Wednesday, August 5, 2020

Janssen Announces Health Canada Approval of DARZALEX®* SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved...

Read more

— Monday, August 3, 2020

Seroprevalence Studies May Underestimate Immunity To The Coronavirus

Globally, there are more than 18 million confirmed novel coronavirus infections. A question many have is...

Read more

— Monday, August 3, 2020

Emerging drugs for the treatment of light chain amyloidosis

Systemic AL amyloidosis is a protein-misfolding disorder that is characterized by the deposition of insol...

Read more